Authorisation of Biopharmaceuticals, Biosimilars and Advanced Therapies in Europe

June 6, 2012 6:41 AM

dia eucraf Authorisation of Biopharmaceuticals, Biosimilars and Advanced Therapies in Europe

EUCRAF and DIA are organizing the “Authorization of Biopharmaceuticals, Biosimilars and Advance Therapies in Europe” training course in Basel, Switzerland between 17-19 September 2012.

EUCRAF (European Centre for Regulatory Affairs Freiburg) and DIA (Drug Information Association) are organizing this 3-day training course focuses on the highly important contribution of biopharmaceuticals to new  drug development. As the functions of biopharmaceuticals are fully explored and utilised, they will  become increasingly relevant to the drug development community.

The key topics of this training course are:

• Definition and characteristics of biopharmaceuticals
• Topics of particular relevance to biopharmaceuticals such as comparability, immunogenicity, adventitious safety, bioassay
• ATMPs
• Biosimilar medicinal products
• Modules 3, 4 and 5 of the EU CTD of biopharmaceuticals
• Regulatory pathways for scientific advice, clinical trials and marketing authorisations of biopharmaceuticals

If you are interested, you can reach more information from here:

Would you like to post an event on Biosimilar News?

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


 

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!